Intelligent Bio Solutions Inc. (INBS)

The investment case for this medical device company is currently broken by a catastrophic multi-year price collapse and deteriorating fundamentals. Despite a recent surge in revenue growth of 45.5%, the stock has erased nearly 99.8% of its value over the last four years, with every single year showing negative returns. This relentless downward trajectory suggests the market views the current business model as fundamentally flawed or facing existential threats that outweigh the recent top-line gains. The balance sheet reflects this distress, with negative free cash flow, negative operating margins, and negative return on equity, indicating the company is burning cash without generating sustainable profits. While the forward P/E appears attractive at 6x, it is based on estimated earnings of just $0.35, implying a turnaround story that remains unproven given the historical performance. With no dividend to provide income and a stock price hovering near its 52-week low, there is no margin of safety for investors. The recent news of partnerships and clinical studies offers hope for a future turnaround, but the current data paints a picture of a company struggling to survive rather than a compelling opportunity to buy.